Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 195.00 | |
5 mg | Inquiry | $ 437.00 | |
10 mg | Inquiry | $ 655.00 | |
25 mg | Inquiry | $ 1,178.00 | |
50 mg | Inquiry | $ 1,768.00 | |
100 mg | Inquiry | $ 2,652.00 | |
200 mg | Inquiry | $ 3,978.00 |
Description | NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA). |
In vivo | In the Line 61 transgenic mouse model overexpressing human wild type ASYN, NPT200-11 (5 mg/kg; i.p.) results in a time-dependent and progressive reduction in retinal ASYN pathology. NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function[1]. |
Molecular Weight | N/A |
CAS No. | 2227057-23-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NPT200-11 2227057-23-8 Others NPT200 11 NPT20011 inhibitor inhibit